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Guinea pigs received a bolus of gentamicin (10 mM for 5 mln) by perilymphatic perfusion which normally led to an Irreversible 
loss of the cochlear microphonic potential (CM). Various experimental conditions that reduced the endolymphatlc potential (FP) were 
then superimposed on the gentamicin application. Reversible reductions in EP (and, concomitantly. In CM) were induced by asphyw 
(3 min). intravenous furosemide ( 50 mg/kg). and perilymphatic perfusion of aminoowyacetic acid (10 mM). When the administration 
of gentamlcin was initiated at the time of maximal EP reduction the usual irreversible gentamicln-Induced dccllnc of <‘M ~a5 
prevented. 
The results indicate that a metabolic process is essential in the expression of gentamicin towcity. The data are consi.\tent with the 
Inhibition of an energy-dependent transport of the aminoglycoside. Alternatively, the data are also compatible with the hypothesis 
that entry of gentamicin into hair cells is prevented by a reduction in their tran\membrane electrical potential. 
aminoglycosides, ototoxicity. gentamicin. energy-dependent uptake, transmembrane potential 
Introduction 
Based on several lines of evidence, this labora- 
tory has formulated a hypothesis to explain the 
acute and chronic ototoxic actions of aminoglyco- 
sides in the inner ear [16,20,21]. In the course of 
their action, the aminoglycosides appear to occupy 
at least two different cellular compartments. Peri- 
lymphatic perfusions of the guinea pig cochlea 
with gentamicin reduced the cochlear microphonic 
potential (CM) with an initial acute phase that was 
readily reversed by the addition of calcium; this 
was followed by a second phase insensitive to 
calcium [23]. Pharmacokinetic data demonstrated 
two different half-lives of gentamicin in cochlear 
tissues prior to and after the onset of chronic 
toxicity [25]. Consistent with these data would be a 
binding of gentamicin to the external cell surface 
as a first step (first compartment) and binding to 
intracellular components such as polyphos- 
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phoinositides in the second compartment [21,26]. 
It would have to be postulated that an uptake 
process transfers the drug from the outside to the 
inside of the cell. Some aspects of aminoglycoside 
uptake in the kidney [1,11] have been char- 
acterized but more detailed analyses have been 
carried out in bacteria where two distinct energy- 
dependent phases of uptake are documented [lo]. 
There is no information on aminoglycoside uptake 
mechanisms in the cochlea. 
The generation and maintenance of a trans- 
membrane potential across the cytoplasmic mem- 
brane is a basic feature of all living cells. This 
potential and the distribution of ions associated 
with it play an essential role in membrane associ- 
ated phenomena such as ionic conductance and 
transport processes. Recently. evidence has been 
presented that the magnitude of the transmem- 
brane potential in bacterial cells is a determining 
factor in aminoglycoside uptake and bactericidal 
action [9]. Thus, more negative membrane poten- 
tials produced greater aminoglycoside uptake and 
enhanced bactericidal effects. A relationship of the 
transmembrane potential to aminoglycoside oto- 
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toxicity is particularly attractive in view of the 
selective actions of aminoglycosides on outer hair 
cells which have been shown to have a more 
negative membrane potential than inner hair cells 
PI. 
The present study was undertaken to test 
whether aminoglycoside actions are related to en- 
ergy-dependent phenomena. The effects of 
gentamicin in perilymphatic perfusions on CM 
were studied under conditions of reduced endo- 
lymphatic potentials (EP). A reduction in EP by 
the experimental manipulations was assumed to be 
an indicator of reduced energy for the mainte- 
nance of transmembrane potentials and of trans- 
port processes of cochlear cells. 
Materials and Methods 
Experiments were performed on male guinea 
pigs (Hartley) weighing 250-400 g. Surgical and 
perilymphatic perfusion techniques were essen- 
tially as previously described [16,17,23]. An animal 
with a positive Preyer reflex was anesthetized with 
sodium pentobarbital (20 mg/kg body wt.. i.p.), 
atropine sulfate (0.05 mg/kg body wt., s.c.) and 
Innovar (0.5 ml/kg body wt., i.m. containing 0.4 
mg fentanyl and 20 mg droperidol/ml). Rectal 
temperature was maintained at 37 t- l°C with a 
heating pad and artificial respiration provided 
through a tracheal cannula. 
The EP was measured with a 3 M KC1 micro- 
electrode inserted through the spiral ligament of 
the basal turn [14]. Perilymphatic perfusions were 
performed via glass capillaries implanted into the 
basal turn of Scala tympani and Scala vestibuli. 
The perfusion pipettes were placed prior to inser- 
tion of the EP recording electrode. The flow of 
perfusate was initiated after establishing a stable, 
positive EP. The CM was measured from a record- 
ing electrode in the Scala tympani perfusion pipette 
and a reference electrode in the superficial mas- 
seter muscle. The CM was recorded in response to 
a sound stimulus of white noise, 20-4000 Hz, 
delivered to the external auditory meatus through 
an earphone coupled to an ear speculum. The 
sound intensity was adjusted to approximately 70 
dB SPL to give an initial CM of 200-400 nV 
(RMS). 
Perilymphatic spaces were perfused at a rate of 
approximately 30 pl/min with artificial perilymph 
containing 130 mM NaCl, 5 mM KU, 1 mM 
CaCl,, 2 mM MgCl,, 0.1 mM NaH,PO,, 10 mM 
NaHCO,, 5 mM glucose and 10 mM Hepes, final 
pH, 7.4. Gentamicin sulfate was dissolved in the 
artificial perilymph at a concentration of 10 mM 
and the pH adjusted with NaOH. After CM and 
EP had stabilized for 30 min the ‘control per- 
fusate’ was switched to the ‘experimental per- 
fusate’ containing drug. Gentamicin was perfused 
for 5 min whereafter perfusion with the control 
perfusate was resumed. Experiments were usually 
carried out for 90-120 min but perfusions without 
drugs could be extended for up to 3 h without 
major (< 20%) loss of CM. Animals with an initial 
CM of less than 200 PV or with an unstable CM 
and EP during the control period (loss of > 10%) 
were eliminated from the study. Amino-oxyacetic 
acid (10 mM) was dissolved in artificial perilymph 
and the pH adjusted with NaOH. Furosemide (50 
mg/kg body weight) was injected over 90 s in- 
travenously via a catheter in the left jugular vein. 
Anoxia was induced by shutting off the respirator. 
Furosemide and aminooxyacetic acid (AOAA) 
were purchased from Sigma. Gentamicin sulfate 
was a gift from the Schering Corporation (Bloom- 
field, NJ). 
Results 
Gentamicin at a concentration of 10 mM per- 
fused as a bolus through the perilymphatic space 
for 5 min drastically reduced the microphonic 
potential but had no effect on the endolymphatic 
potential (Fig. 1 and Table I). The CM began to 
decline rapidly within 30 s after gentamicin en- 
tered the cochlea and continued to decline, al- 
though after the 5 min perfusion the perfusate no 
longer contained the drug. Consistently, a 60% 
reduction of CM was reached after 60 min. This 
irreversible action of gentamicin on CM and its 
lack of effect on EP have been described before 
[12,13]. 
Anoxia induced by turning the respirator off 
produced a rapid decline in EP and CM (Fig. 2). 
This effect rapidly and completely reversed if the 
respirator was turned back on after 3 min (Fig. 2 
and Table I) consistent with reports by others [14]. 
When the perilymphatic space was perfused with 
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Fig. 1. Time course of gentamicin action on endolymphatic and 
cochlear microphonic potentials. Techniques for carrying out 
perilymphatic perfusions and recording EP and CM were as 
described in Materials and Methods. Following the control 
perfusion (‘stabilizing period’. -30 to 0 min), the perfusate 
10 mM gentamicin for 5 min beginning at a time 
when EP and CM were suppressed by asphyxia 
the usual irreversible actions of gentamicin on CM 
were prevented (Fig. 2 and Table I). One hour 
after anoxia plus gentamicin. CM had recovered to 
97 & 6% of its pre-drug control value (Table I) 
whereas one hour after gentamicin alone. CM was 
40 & 2% of its pre-drug value (Table I). 
Following intravenous injections of a bolus of 
furosemide (50 mg/kg), the endolymphatic poten- 
tials fell rapidly to near zero values (Fig. 3). The 
peak suppression of EP and CM occurred in less 
than 2 min. This was followed by a quick recovery 
of EP by about 20-30 mV, a plateau and then a 
gradual recovery to pre-injection values (Fig. 3). 
The CM followed a similar time course of recovery 
was changed at the point indrcated for 5 mm to experimental 
perfusate containing 10 mM gentamicin (Cm). Curves are 
mean values from 4 animals (EP) and 5 animals (CM). Note 
the lack of effect of gentamicin on the EP. 
TABLE I 
EFFECT OF DRUG TREATMENTS ON COCHLEAR POTENTIALS 
See Figs. l-4 for experimental conditions. 
A. Endolymphatic potential 
Treatment Control Minimum Recovered 
(mv) (mv) 
Gentamicin uo+ 4 78*3 
Anoxia 82k 5 -11+ 6 81+4 
Anoxia + Gm 80* 6 -3+13 82k5 
Anoxia + Gm X0*6 
Furosemide + Gm 84+ 4 12* 1 72+5 
AOAA + Gm 81kll 18* 7 16+3 
B. Cochlear microphonics 
Treatment Minimum Recovered 
(% of control) 
Gentamicm 40+2 
Anoxia 47+10 loo*2 
Anoxia + Gm 46+11 97+4 
Anoxia + Gm 9lk6 
Furosemide 44*11 102&U 
Furosemide + Gm 44* 4 107+8 
AGAA 52?10 72+7 
AOAA -~~ Gm 4s*10 73?8 
Gm ~~ AOAA 41* 4 48+3 
A Time from beginning of treatment to measurement of recovered potential. 
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Fig. 2. Prevention of gentamicin-induced suppression of 
cochlear microphonic potentials during anoxic reduction of the 
endolymphatic potential. Experimental procedures were carried 
out as described in Materials and Methods. Following the 
control perfusion for 30 min the respirator was turned off at 
the time indicated by the arrow. 90 s later the control perfusate 
was changed to experimental perfusate containing 10 mM 
gentamicin (GM) for 5 min. Bar indicates time that gentamicin 
was in the perilymphatic space. After 3 min of asphyxia the 
respirator was turned back on. Thus. CM and EP were markedly 
reduced by anoxia at the time gentamicin entered the cochlea 
and remained suppressed for at least 2 of the 5 min of exposure 
to the drug. -, perfusions without gentamicin; - - - - -. 
perfusions with gentamicin. Note that in contrast to results 
shown in Fig. 1 the CM recovers to pre-drug values. 


















I I I I I 1 
-30 0 30 60 90 
TIME (mitt) 
Fig. 4. Prevention of gentamicin-induced suppression of 
cochlear microphonic potentials during reduction of the endo- 
lymphatic potential by aminooxyacetic acid. Experimental pro- 
cedures were as described in Materials and Methods. Following 
the control perfusion, drugs were introduced into the perfusate 
for the time and sequence indicated by the bars: A. 
aminooxyacetic acid (10 mM); Gm, gentamicin (10 mM). Nore 
the contrast in the recovery of CM depending on the sequence 
of administration of the two drugs. 
and returned to 102 k 8% of its initial value by 90 
min (Table I). These results, again, are compatible 
with previous reports by others [19]. The actions of 
10 mM gentamicin were prevented when the 5 min 
perfusion of gentamicin was initiated at the time 
of peak suppression of EP by furosemide (Fig. 3 
and Table I). With furosemide plus gentamicin, 
Fig. 3. Prevention of gentamicin-induced suppression of 
cochlear microphonic potentials during reduction of the endo- 
lymphatic potential by furosemide. Experimental procedures 
were carried out as described in Materials and Methods. Fol- 
lowing the control perfusion (‘stabilizing period’, -30 to 0 
min), furosemide (Fu) was injected intravenously into the left 
jugular vein as a bolus over 90 s. At the point of maximum CM 
and EP suppression the control perfusate was changed to 
experimental perfusate containing 10 mM gentamicin (GM) for 
5 min. Bar indicates time that gentamicin was in the peri- 
lymphatic space. -, perfusion without gentamicin; - - - - - 
-. with gentamicin. Again, note that in contrast to results 
shown in Fig. 1 the CM recovers to pre-gentamicin values. 
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CM had recovered to 107 + 8% of its initial value 
by 90 min (Table I). 
Perilymphatic perfusion of 10 mM AOAA 
rapidly suppressed EP and CM (Fig. 4). The ef- 
fects of AOAA were reversible but required pro- 
longed periods of perfusion with drug-free per- 
fusate: by 60 min, CM had only recovered to 
72 i 7%’ of pre-AOAA values (Table I). These 
effects of AOAA on cochlear potentials are in 
keeping with reports of others [2,3]. The actions of 
10 mM gentamicin on CM were prevented if the 5 
min gentamicin perfusion began at the time of 
maximal EP and CM suppression (Fig. 4 and 
Table I) by AOAA. In contrast, if the administra- 
tion of gentamicin preceded the perfusion of 
AOAA there was little, if any, recovery of CM 
after 60 min when compared to perfusions of 
gentamicin alone (Table I). 
Discussion 
The salient finding is that the expression of 
gentamicin toxicity requires an active metabolic 
process. This is the broadest interpretation of the 
fact that gentamicin toxicity is prevented when the 
drug is administered during a period of decreased 
endolymphatic potential. In this context the reduc- 
tion of EP is taken as an indicator of interference 
with energy metabolism in cochlear structures. The 
question then arises what this active metabolic 
process is and how it affects the mechanism of 
aminoglycoside toxicity. 
First we may consider the uptake of the drug. 
In the mechanism of the antibacterial activity of 
aminoglycosides it is clearly established that an 
active uptake process precedes the toxic effect of 
the drug [lo] and uptake into the kidney also has 
an energy-dependent component [l]. For the inner 
ear such evidence still is lacking but results pre- 
sented here are compatible with an active drug 
uptake system in the inner ear. When inhibited by 
such manipulations as asphyxia. the drug would 
not penetrate the cells and thus not be toxic. 
The nature of the cochlear uptake system can- 
not be delineated from the present study. A 
target-specific inhibition of a transport system 
seems unlikely since such diverse agents as 
asphyxia. furosemide, and aminooxyacetic acid all 
produced a similar effect. Rather, since all agents 
used inhibit metabolism as indicated by the de- 
crease in EP, an interference with the energy supply 
to such a system may be the common action. Thus, 
any active carrier-mediated transport or ATP-de- 
pendent co-transport of aminoglycosides is com- 
patible with the evidence. If. however. ATP levels 
remain largely unaffected in the hair cells during 
the acute phase of furosemide-induced reduction 
of EP as proposed for the stria vascularis [15] 
more restraints have to be applied to the model. 
An alternative energy-dependent uptake of 
gentamicin could be driven by the transmembrane 
potential of the cells as demonstrated in bacteria 
[9]. The appeal of postulating a potential-related 
uptake in the inner ear is the apparent correlation 
between the susceptibility of inner and outer hair 
cells to aminoglycosides and their potential. In- 
tracellular potentials of cochlear inner hair cells 
and supporting cells, however, show only small 
changes during transient asphyxia [4.18]. It would 
have to be assumed that under the conditions of 
the experiments the major action of the amino- 
glycosides is on the apical end of the hair cells: the 
reduction of the endolymphatic potential would 
lower the driving force for drug entry into the 
cells. Pharmacokinetic evidence for the route of 
access of aminoglycosides to endolymph is not 
entirely clear [24] and endolymph may not be the 
major compartment from which these drugs enter 
the hair cells after systemic injections [25]. 
While an inhibition of drug uptake seems the 
most direct explanation for the observed effects 
other interpretations are possible. For example. an 
inhibition of metabolism would also affect any 
metabolism of the drug itself. Drug metabolism 
may be a crucial determinant in toxicity as in the 
case of the nephrotoxic actions of the antineoplas- 
tic drug. cis-dichlorodiamine platin. The parent 
compound apparently has lower toxicity than its 
metabolites [7]. Considering the design of the ex- 
periments in this study it would have to he pos- 
tulated that the initial step in aminoglycoside 
toxicity is a metabolic transformation and that the 
metabolite, but not the parent compound. will 
penetrate the cell to cause permanent damage. It 
is, however. generally assumed that aminoglyco- 
sides are not metabolized so that this interpreta- 
tion appears less likely. 
An apparent paradox in the current results is 
the fact that the acute combination of two poten- 
tially ototoxic drugs results in reduced ototoxicity 
rather than a potentiation as observed when the 
same drugs are administered systemically. A 
potentiation has been reported for aminoglyco- 
sides in combination with both, furosemide [5] as 
well as aminooxyacetic acid [6]. Several reasons 
may account for this lack of interaction: gentami- 
tin is given here by perilymphatic perfusions pos- 
sibly eliminating the site of interaction; or, that in 
this acute combination neither drug has sufficient 
time to cause the effect that would lead to potenti- 
ation. 
The postulate of an active uptake process for 
aminoglycosides in the cochlea fits well into the 
model we have previously proposed for their 
ototoxicity since phosphoinositides are considered 
to be present in the inner (cytoplasmic) surface of 
the membrane. The drug would first bind to nega- 
tively charged sites on the external plasma mem- 
brane such as acidic phospholipids. This action, 
antagonized by calcium, would account for the 
acute and reversible effects of the aminoglyco- 
sides. Following the uptake into the cells, the 
drugs bind to phosphoinositides, inhibit their 
function and disrupt membrane structure. The sus- 
ceptibility of a tissue to aminoglycosides would 
then depend on both the presence of an uptake 
system and the presence of intracellular sites of 
action, most importantly, phosphoinositides. 
The precise nature of the energy-dependent 
process involved in aminoglycoside toxicity re- 
mains to be elucidated. Both hypotheses raised, 
active carrier-mediated transport or transport by 
membrane potential, are amenable to further test- 
ing in vivo and in vitro. Our finding already points 
to the complexity of the aminoglycoside action in 
the inner ear and shows novel parallels between 
the cochlear and the renal and bacterial handling 
of the drug. 
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